NEWS COMMENTARY

Singaporean digital therapeutics startup Biofourmis raises $35 million for chronic disease management

Published:
June 03, 2019
Coverage:
Digital Transformation More...
Activities:
Investment
by Nardev Ramanathan
Very important

Biofourmis has now brought its total investment raised to over $40 million. It also just obtained FDA 510(k) clearance for RhythmAnalytics, a cloud-based software that uses deep learning to extract and interpret more than 15 types of cardiac arrhythmias. This investment round was led by big-name VCs like Sequioa Capital, MassMutual Ventures, and Singapore government-linked investment arm EDBI. Clients looking to partner with digital therapeutics startups should look at examples like Biofourmis. Biofourmis' partnerships with clinical centers in Singapore and Boston allows it to validate its product in Asian and American demographics in parallel, which addresses unique population differences and enables its product to reach a larger market.

For the original news article, click here .


Further Reading

Bill Gates invests in Indonesian online healthcare platform Halodoc

News Commentary | July 25, 2019

Halodoc has secured $65 million in a Series B round from strategic investors that also include insurers Allianz X and Prudential. What's interesting is that this also marks the Bill & Melinda Gates Foundation's first equity investment in an online healthcare platform. While Bill Gates has ... Not part of subscription

DayTwo raises additional $5 million in Series B funding from group of strategic investors

News Commentary | October 08, 2019

The strategic investors are Longliv Ventures, a member of CK Hutchison Holdings Group, the global VC partnership Cathay Innovation, and Samsung NEXT. To date, DayTwo has mainly focused on the Israel and U.S. markets. With these new investors, DayTwo signals that it is ramping up for expansion into ... Not part of subscription

Sanofi backs out from its digital diabetes and cardiovascular programs

News Commentary | December 17, 2019

This announcement effectively ends Sanofi's partnership with Onduo, a joint venture with Verily. Back in 2016, both Verily and Sanofi invested half a billion dollars in this ambitious program, with Sanofi execs touting this as an example of their commitment to digital health innovation. Onduo has ... Not part of subscription